Use of pharmacoeconomics in prescribing research. Part 2: Cost-minimization analysis - When are two therapies equal?

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 2, 2003, Pages 145-150

  Newby, David ^a   Hill, S ^b  

^a NEWCASTLE MATER HOSPITAL   (Australia)

^b NONE

Author keywords

Cost minimization analysis; Equivalance studies; Pharmacoeconomics

Indexed keywords

ANTIDEPRESSANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DOSE RESPONSE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MEDICAL ASSESSMENT; MOLECULAR SIZE; RANDOMIZED CONTROLLED TRIAL;

COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; EXPERT TESTIMONY; THERAPEUTIC EQUIVALENCY;

EID: 0037992921     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00455.x     Document Type: Article

References (16)

1. Freund D, Dittus R. (1992) Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics, 1, 20-32.
2. Greive A. (1998) Issues for statisticians in pharmacoeconomic evaluations. Statistics in Medicine, 17, 1715-1723.
3. Rohmel J. (1998) Therapeutic equivalence investigations: statistical considerations. Statistics in Medicine, 17, 1703-1714.
4. Altman D, Bland J. (1995) Absence of evidence is not evidence of absence. BMJ, 311, 485.
5. Briggs A, O'Brien B. (2001) The death of cost-minimization analysis? Health Economics, 10, 179-184.
6. Jones B, Jarvis P, Lewis J, Ebbutt A. (1996) Trials to assess equivalence: the importance of rigorous methods. BMJ, 313, 36-39.
7. Djulbegovic B, Clarke M. (2001) Scientific and ethical issues in equivalence trials. JAMA, 285, 1206-1208.
8. Anonymous. (1998) Tri-council policy statement: Ethical Conduct for Research Involving Humans [online]. Available: http://www.nserc.ca.programs/ethics/english/ethics-e.pdf. Accessed 19 June 2002.
9. Commonwealth Department of Human Services and Health. (1995) Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Australian Government Publishing Service.
10. Cubeddu L, Hoffmann I, Fuenmayor N, Finn A. (1990) Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. New England Journal of Medicine, 322, 810-816.
11. Anonymous. (1992) A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. European Neurology, 32, 177-184.
12. Heaney D, Shorvon S, Sander J et al. (2000) Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia, 41(Suppl. 5), S37-S44.
13. Howard K, Blumenschein K, Rapp R. (1999) Azithromycin versus erythromycin for community acquired pneumonia: a cost-minimization analysis. American Journal of Health System Pharmacy, 56, 1521-1524.
14. Salewski E, Bassaris H, Calangu S et al. (1999) Cost-minimisation analysis of sequential treatment with ofloxacin or ciprofloxacin in hospitalised patients. Pharmacoeconomics, 11, 359-366.
15. Rubio-Terre's C, Tisaire J, Kobina S, Moyano A. (2002) Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. Lung Cancer, 35, 81-89.
16. Sweetenham J, Hieke K, Kerrigan M et al. (1999) Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. British Journal of Haematology, 106, 47-54.